Monday, April 29, 2013

Sickle cell disease accounts for many priapism cases



NEW YORK (Reuters Health) - Thanks to commercials for erectile dysfunction drugs, men know to seek medical attention for "erections lasting more than four hours," but a new study suggests a blood disorder is the cause of many prolonged erections.
While the condition - formally known as priapism - is rare, researchers report in The Journal of Urology that between 14 percent and 30 percent of cases that show up in U.S. emergency rooms are men with sickle-cell disease.
"I would say what the paper is telling us is that sickle-cell disease is still responsible for the bulk of the visits for priapism," said Dr. Gregory Broderick, professor of urology at the Mayo Clinic in Jacksonville, Florida, who was not involved in the study.


Prostate cancer screening for older men 'unlikely'

 NHS Choices (Wed April 17, 2013)

There is wide coverage of new research that argues that routine screening could reduce deaths from prostate cancer, with BBC News, The Daily Telegraph and the Daily Mail all reporting the story. This controversial study is likely to reignite the debate about whether routine screening for prostate cancer does more harm than good.

Read the full NHS report

Wednesday, April 10, 2013

Doctors group questions prostate cancer screening

(Reuters Health)

The American College of Physicians (ACP) became the latest group to ask doctors to be clear about the limited benefits and "substantial harms" of prostate cancer screening before offering their male patients a prostate-specific antigen (PSA) test.


The ACP's guidance statement, published Monday in the Annals of Internal Medicine, also explicitly recommends against screening men younger than 50, older than 69 or with less than 10 to 15 years to live.

Men in their 50s and 60s may weigh the potential benefits and harms of PSA testing differently, which is why the idea of shared decision-making between patients and their doctors is so critical, said the ACP's Dr. Amir Qaseem.

Read the full Reuters Health report

Friday, April 5, 2013

Testosterone doesn't boost functioning in older men

(Reuters Health) - Older men who use testosterone gel may see small improvements in their muscle-to-fat ratio but are unlikely to glean any benefits in flexibility, endurance and general ability to get around, new research suggests.

Read More

Wednesday, April 3, 2013

Urine Biomarker Combo Predicts Prostate Cancer

Medscape News
MILAN, Italy

A combination of 2 urine-based genetic biomarkers predicts prostate cancer better than either biomarker alone and better than the standard serum prostate-specific antigen (PSA), according to a new study.

The 2 markers, PCA3 and the TMPRSS2:ERG gene fusion "can help stratify men for risk of cancer, significant cancer, and high-grade cancer at biopsy," said Jack Groskopf, PhD, director of oncology research and development at Hologic Gen-Probe in San Diego, California.

The company is currently developing both biomarkers. "We're hoping to show that the urine test results can help predict the probability of a positive biopsy and the probability that the biopsy will find clinically significant cancer that needs to be treated," Dr. Groskopf told Medscape Medical News.

Read More

Saturday, March 9, 2013

Even for sperm, there is a season


(Reuters Health) -

Autumn is the time of year most associated with bumper crops of new babies, and that may be because human sperm are generally at their healthiest in winter and early spring, according to a new study from Israel.

Based on samples from more than 6,000 men treated for infertility, researchers found sperm in greater numbers, with faster swimming speeds and fewer abnormalities in semen made during the winter, with a steady decline in quality from spring onward.

Read the full Reuters Health report

Thursday, March 7, 2013

Irradiation Produces Durable Survival in Prostate Cancer

In prostate cancer, radiation therapy and radical prostatectomy produce "durable disease control."

In fact, 15-year disease-free survival rates with the 2 treatments are similar, according to a new study published in the March issue of the Journal of Urology.

However, the researchers found that prostate cancer can recur after many years. Therefore, they recommend that patients be followed for at least 15 years after their initial treatment.

Click here for the fully Medscape report
(free sign-up may be required)